Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease

Figure 1 Kaplan-Meier curves for time to complete response. A: Stratified by diagnosis (atypical hyperplasia vs grade 1 endometrioid adenocarcinoma); B: Stratified by Ki-67 status (≤ 20% vs > 20%); C: Stratified by human epididymis protein 4 status (≤ 50 pmol/L vs > 50 pmol/L). HE4: Human epididymis protein 4.

Figure 2 Distribution of fertility-sparing treatment modalities. LNG-IUD: Levonorgestrel-releasing intrauterine device; MA: Megestrol acetate.

Figure 3 Recurrence rates by body mass index category. BMI: Body mass index.

Figure 4 Ki-67 vs human epididymis protein 4 by recurrence status. HE4: Human epididymis protein 4.

Figure 5 Complete response rates by molecular classification. MMRd: Mismatch repair deficient; NSMP: No specific molecular profile; P53abn: P53 abnormal; POLEmut: POLE-mutated (DNA polymerase epsilon-mutated).